ArticleJournal of pharmacogenomics & pharmacoproteomics2014
Beyond IC
Article in Journal of pharmacogenomics & pharmacoproteomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A Pyrone Glucoside fromBiomolecules · 2026Article
- Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.Communications medicine · 2026Article
- Development and Characterization of pFluor50, a Fluorogenic-Based Kinetic Assay System for High-Throughput Inhibition Screening and Characterization of Time-Dependent Inhibition and Inhibition Type for Six Human CYPs.Molecules (Basel, Switzerland) · 2025Article
- Neonicotinoid insecticides exert diverse cytotoxic and genotoxic effects on cultivated sunflower.Environmental science and pollution research international · 2021Article
- Cellular and Acellular Assays for Measuring Oxidative Stress Induced by Ambient and Laboratory-Generated Aerosols.Research report (Health Effects Institute) · 2019Article
- Article
- An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines.Frontiers in pharmacology · 2017Review
- A data-driven weighting scheme for multivariate phenotypic endpoints recapitulates zebrafish developmental cascades.Toxicology and applied pharmacology · 2017Article
- Estimating Potency in High-Throughput Screening Experiments by Maximizing the Rate of Change in Weighted Shannon Entropy.Scientific reports · 2016Article
- Quantitative high-throughput screening data analysis: challenges and recent advances.Drug discovery today · 2015Article
- Identifying genes that mediate anthracyline toxicity in immune cells.Frontiers in pharmacology · 2015Article
- Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics.Pharmacogenomics and personalized medicine · 2015Article
- An investigation of gene-gene interactions in dose-response studies with Bayesian nonparametrics.BioData mining · 2015Article
- Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.Current molecular medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cell line cytotoxicity assays have become increasingly popular approaches for genetic and genomic studies of differential cytotoxic response. There are an increasing number of success stories, but relatively little evaluation of the statistical approaches used in such studies. In the vast majority of these studies, concentration response is summarized using curve-fitting approaches, and then summary measure(s) are used as the phenotype in subsequent genetic association studies. The curve is usually summarized by a single parameter such as the curve's inflection point (e.g. the EC/IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.